Boston Scientific Corp. (BSX)

From the record

Boston Scientific Corp.'s filings since 2017 show 1 warning event: a material cybersecurity incident (8-K item 1.05, the latest 2026-09-08) (its current reports).

From the record

Boston Scientific Corp.'s 10 filed years say what it did: revenue went from $8.4 billion in fiscal 2016 to $20 billion in fiscal 2025, up 10.2% a year; it rose in 8 of 9 years; the deepest fall was 8% from fiscal 2019 to fiscal 2020; net income was positive in 9 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Boston Scientific Corp.'s diluted share count grew about 1.3% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 3 sales (3 under scheduled 10b5-1 plans) and 10 purchases of their own stock on the open market in the year to 2026-11-06, buying about $10 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Boston Scientific Corp. earned about 12 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 32 cents per dollar of everything the company owns. Leverage: it owed about 44 cents per dollar of assets, and net share issuance: its share count grew 0.6% over the year (the filed statements).

From the record

Boston Scientific Corp.'s standing among 109 graded names in its industry family: revenue of $20 billion in fiscal 2025 ranks in the top 4% by size; a net margin of 14.4% ranks in the top 12%; revenue growth of 16.5% a year over the last 3 filed years ranks in the top 45% (its annual reports).

From the record

Boston Scientific Corp.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Mahoney, Michael F (Chairman, President & CEO, as filed), filing under that title since 2012-11-05, 14 years (top 6% of its family); the 17 officers and directors filing in the last fifteen months have been on the record a median of 3.4 years (bottom 17%); 14 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (bottom 28%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Boston Scientific Corp.'s room to grow, from the newest filed statements (fiscal 2025): cash of $2.0 billion against debt of $11 billion leaves -21% of its assets as net cash, bottom 17% of its family; cash from operations less capital spending is 18.2% of revenue (top 10%); a gross margin of 69% (top 33%); research spending of 10.2% of revenue (bottom 45%) (its annual report).

From the record

Boston Scientific Corp.'s growth drivers, from the filed years to fiscal 2025: revenue grew 16.5% a year over the last three filed years against 10.2% over all 10, speeding up (top 16% of its family); the newest year grew 19.9% (top 33%); research spending grew 15.8% a year (top 26%); capital spending grew 14.2% a year (top 32%) (its annual reports). Boston Scientific Corp. reported 2 lines of business in fiscal 2025: Cardiovascular at $13 billion, Medsurg at $6.8 billion. 2 of 2 grew in the latest filed year, and the largest line is 66% of revenue (its annual report).

From the record

Boston Scientific Corp.'s newest year against its own record: revenue of $20 billion in fiscal 2025 came in 4.3% above the $19 billion its prior three years' pace pointed to (top 26% of its family); net income of $2.9 billion against a prior three-year average of $1.4 billion (top 14%); a net margin of 14.4% against 9.2% before (bottom 40%) (its annual reports).